Join the Diabetic Retinopathy group to help and get support from people like you.
Diabetic Retinopathy News
Cholesterol Med, Fenofibrate, Might Slow Vision Loss in People With Diabetes
TUESDAY, June 25, 2024 – A well-established cholesterol-lowering drug appears to significantly slow the progression of a diabetes-related eye disease, a new trial shows. Fenofibrate (Tricor) has...
Cholesterol Med, Fenofibrate, Might Slow Vision Loss in People With Diabetes
TUESDAY, June 25, 2024 – A well-established cholesterol-lowering drug appears to significantly slow the progression of a diabetes-related eye disease, a new trial shows. Fenofibrate (Tricor) has...
FDA Approves Yesafili (aflibercept-jbvf), an Interchangeable Biosimilar to Eylea
May 20, 2024 – The U.S. Food and Drug Administration (FDA) has approved Yesafili (aflibercept-jbvf), an interchangeable biosimilar to Eylea (aflibercept). Aflibercept products work by inhibiting...
FDA Approves Opuviz (aflibercept-yszy), an Interchangeable Biosimilar to Eylea
May 20, 2024 – The U.S. Food and Drug Administration (FDA) has approved Opuviz (aflibercept-yszy), an interchangeable biosimilar to Eylea (aflibercept). Aflibercept products work by inhibiting...
Diabetes Complications More Common in Patients Not Living in Urban Areas
WEDNESDAY, March 27, 2024 – Adults with diabetes living in small towns are disproportionately impacted by complications of diabetes, according to a study published online Feb. 22 in Diabetes Care. ...
Machine Learning Can Predict Eyes at Risk for Diabetic Retinopathy Progression
TUESDAY, Feb. 13, 2024 – Automated machine learning models may help identify eyes at risk for diabetic retinopathy (DR) progression based on ultra-widefield retinal images, according to a study...
Diabetic Retinopathy Tied to Lower Vision-Related Quality of Life
TUESDAY, Feb. 6, 2024 – Vision-related quality of life (VRQoL) declines with the presence and higher severity of diabetic retinopathy (DR), according to a review published online Feb. 1 in JAMA ...
Artificial Intelligence Increases Diabetic Eye Exams in Youth With Diabetes
TUESDAY, Jan. 16, 2024 – For youth with diabetes, an autonomous artificial intelligence diabetic eye exam at the point of care is associated with increased diabetic eye exam completion rates within...
American Academy of Ophthalmology, Nov. 3-5
The annual meeting of the American Academy of Ophthalmology was held from Nov. 3 to 5 in San Francisco and attracted participants from around the world, including ophthalmologists, optometrists,...
Wegovy, Ozempic Probably Won't Harm Vision in People With Diabetes, Study Finds
THURSDAY, Nov. 9, 2023 (HealthDay) – There's good news for people with diabetes who are turning to drugs like Ozempic and Wegovy to treat their disease and lose weight: The drugs probably will not...
AAO: Diabetic Retinopathy Usually No Worse With Semaglutide in T2D
THURSDAY, Nov. 9, 2023 – For patients with type 2 diabetes mellitus, most eyes have no worsening of diabetic retinopathy (DR) after initiation of semaglutide, according to a study presented at the...
FDA Approves Eylea HD (aflibercept) Injection 8 mg for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)
TARRYTOWN, N.Y., Aug. 18, 2023 (GLOBE NEWSWIRE) – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Eylea HD (aflibercept)...
FDA Approves Cimerli (ranibizumab-eqrn), an Interchangeable Biosimilar to Lucentis
REDWOOD CITY, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) – Coherus BioSciences, Inc. (Coherus or Coherus BioSciences, Nasdaq: CHRS) announced today that the U.S. Food and Drug Administration (FDA) has...
FDA Approves Eylea (aflibercept) Injection for Diabetic Retinopathy
TARRYTOWN, N.Y., May 13, 2019 /PRNewswire/ – Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Eylea (aflibercept) Injection to treat all...
FDA Approves Genentech’s Lucentis (ranibizumab injection) 0.3 mg Prefilled Syringe for Diabetic Macular Edema and Diabetic Retinopathy
South San Francisco, CA – March 21, 2018 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved the...
Ask a question
To post your own question to this support group, sign in or create an account.